Interpreting Intensification Strategies in Metastatic Castration-Sensitive Prostate Cancer

In this segment, Dr. Graham and Dr. Sokolova examine how clinicians interpret the broader evidence base in metastatic castration-sensitive prostate cancer when selecting among different treatment intensification strategies. The discussion addresses data from studies evaluating approaches such as chemotherapy and alternative androgen pathway–targeted therapies, emphasizing that direct cross-trial comparisons are not available. Dr. Graham highlights the importance of synthesizing evidence across trials while accounting for differences in study design, patient populations, and clinical endpoints. Both experts stress that treatment selection should be individualized, incorporating disease characteristics, patient comorbidities, and treatment goals rather than relying on isolated data points. The conversation reinforces that understanding the collective body of evidence supports more informed and nuanced decision-making. Overall, this segment underscores the role of clinical judgment in applying trial data to real-world care for patients with mCSPC.